AEM vs CC

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

The Chemours Company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 17.51. While the stock has seen a massive 1-year price surge of 119.6%, this momentum is decoupled from fundamentals, as evidenced by a negative ROE of -93.80% and shrinking revenue. The dividend is unsustainable with a payout ratio of 555.56%, and the current price of $26.61 already exceeds the analyst target price of $21.67. Overall, the company appears to be in a high-risk state with significant solvency concerns.